Related Experiment Video
Updated: Aug 19, 2026

A Two-Step Method for Percutaneous Transhepatic Choledochoscopic Lithotomy
Published on: September 13, 2022
Marked elevation in serum transaminases: an atypical presentation of choledocholithiasis
Rahul A Nathwani1, S Ram Kumar, Telfer B Reynolds
1Division of Gastrointestinal and Liver Disease, Department of Medicine, Keck School of Medicine/University of California-Los Angeles, 2011 Zonal Avenue, HMR#101, Los Angeles, CA 90033, USA.
Background:
Choledocholithiasis causes elevations in levels of alkaline phosphatase out of proportion to aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Isolated marked elevation in AST and ALT levels over 1,000 IU/L has been reported infrequently in patients with choledocholithiasis.
Methods:
The charts of 18 patients who presented between 1971 and 2002 with documented choledocholithiasis and AST or ALT levels greater than 1,000 IU/L were retrospectively reviewed. An extensive work-up for coexisting disease processes to account for the abnormal AST and ALT levels was negative.
Results:
Eighteen patients (16 women, 16 Hispanics, age 38 +/- 3 yr) presented with symptoms of choledocholithiasis and marked transaminase elevation. Peak levels of AST and ALT were 1,062 +/- 129 and 1,119 +/- 90, respectively. Following successful management of gallstone disease, AST and ALT levels fell rapidly to 129 +/- 22 and 268 +/- 61, respectively, within 3-14 days. There was also a concomitant improvement in the levels of bilirubin and alkaline phosphatase.
Conclusions:
In the absence of other hepatobiliary or pancreatic disease, choledocholithiasis can result in elevations in AST and/or ALT greater than 1,000 IU/L. These levels fall markedly once the gallstone disease is appropriately managed.
Related Concept Videos
Cholecystitis
Endoscopic Procedures V: ERCP
Patient...
Acute Pancreatitis I: Introduction
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Acute Pancreatitis II: Clinical Manifestations and Management
Chronic Pancreatitis II: Collaborative Care
Assessment: